Cygnus 产品代理

Cygnus   Technologies, part of Maravai LifeSciences, is the biopharmaceutical industry’s partner in host   cell protein (HCP) and other process-related impurity detection and   analytics. In addition, Cygnus now provides innovative viral clearance   solutions as well.

Cygnus helps   companies developing therapeutic proteins, vaccines, antibodies, plasma   derivatives and gene therapies to ensure the safety of biotherapeutics prior   to human trials, regulatory approval and commercial release. Cygnus provides   analytical tools and solutions delivering insights to improve bioprocess   development for faster regulatory approval and better clinical outcomes. 

Cygnus is an industry pioneer responsible for developing and 

commercializing   the first generic assay kits for HCP detection. Its reputation for quality is   recognized by the industry and global regulatory agencies. It continues to   advance the science of bioprocess impurity detection with new breakthroughs,   including its Antibody Affinity Extraction™ (AAE) technology and orthogonal methods of HCP analysis that   integrate Mass Spectrometry, AAE and ELISA. To reduce the cost and risk   associated with viral clearance studies, Cygnus also offers a unique approach   that utilizes non-infectious mock virus particles through its MockV™ virus clearance   kits.

Cygnus’ proprietary   technology, available through its off-the-shelf and custom analytics   programs, sets the gold standard for enabling HCP and other bioprocess   impurity antibody assays. Cygnus delivers best-in-class customer service and   technical expertise, operational excellence and ISO-9001:2015 certified   quality management systems.

Founded by Ken Hoffman in 1997, Cygnus continues to support and advance technology in order to improve biotherapeutic safety and accelerate the movement of new therapeutics through the development and regulatory approval process.